JP5496899B2 - シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン - Google Patents

シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン Download PDF

Info

Publication number
JP5496899B2
JP5496899B2 JP2010530110A JP2010530110A JP5496899B2 JP 5496899 B2 JP5496899 B2 JP 5496899B2 JP 2010530110 A JP2010530110 A JP 2010530110A JP 2010530110 A JP2010530110 A JP 2010530110A JP 5496899 B2 JP5496899 B2 JP 5496899B2
Authority
JP
Japan
Prior art keywords
compound
cancer
pharmaceutically acceptable
acceptable salt
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010530110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500713A5 (OSRAM
JP2011500713A (ja
Inventor
グレゴリー エス ハミルトン
尚 塚本
ダナ ヴィー ファラリス
ブリジェット デュヴァル
レナ ラピダス
Original Assignee
エイザイ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40251685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5496899(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エイザイ インコーポレイテッド filed Critical エイザイ インコーポレイテッド
Publication of JP2011500713A publication Critical patent/JP2011500713A/ja
Publication of JP2011500713A5 publication Critical patent/JP2011500713A5/ja
Application granted granted Critical
Publication of JP5496899B2 publication Critical patent/JP5496899B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2010530110A 2007-10-16 2008-10-16 シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン Active JP5496899B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98039707P 2007-10-16 2007-10-16
US60/980,397 2007-10-16
PCT/US2008/080163 WO2009052287A1 (en) 2007-10-16 2008-10-16 2 ' -flu0r0-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014043175A Division JP5859588B2 (ja) 2007-10-16 2014-03-05 シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン

Publications (3)

Publication Number Publication Date
JP2011500713A JP2011500713A (ja) 2011-01-06
JP2011500713A5 JP2011500713A5 (OSRAM) 2011-12-01
JP5496899B2 true JP5496899B2 (ja) 2014-05-21

Family

ID=40251685

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010530110A Active JP5496899B2 (ja) 2007-10-16 2008-10-16 シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン
JP2014043175A Active JP5859588B2 (ja) 2007-10-16 2014-03-05 シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014043175A Active JP5859588B2 (ja) 2007-10-16 2014-03-05 シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン

Country Status (39)

Country Link
US (4) US8268800B2 (OSRAM)
EP (2) EP2207786B1 (OSRAM)
JP (2) JP5496899B2 (OSRAM)
KR (1) KR101543049B1 (OSRAM)
CN (1) CN101827856B (OSRAM)
AT (1) ATE548374T1 (OSRAM)
BR (1) BRPI0818672B8 (OSRAM)
CA (1) CA2702274C (OSRAM)
CO (1) CO6270330A2 (OSRAM)
CR (1) CR11427A (OSRAM)
CY (3) CY1112781T1 (OSRAM)
DK (1) DK2207786T3 (OSRAM)
EA (1) EA018757B1 (OSRAM)
EC (1) ECSP10010095A (OSRAM)
ES (2) ES2616566T3 (OSRAM)
FI (2) FIC20230039I1 (OSRAM)
FR (2) FR23C1051I2 (OSRAM)
GT (1) GT201000088A (OSRAM)
HR (1) HRP20120419T1 (OSRAM)
HU (2) HUS2300044I1 (OSRAM)
IL (1) IL204732A (OSRAM)
JO (1) JO2778B1 (OSRAM)
LT (2) LTPA2023539I1 (OSRAM)
ME (1) ME00997B (OSRAM)
MX (1) MX2010004109A (OSRAM)
MY (1) MY147970A (OSRAM)
NI (1) NI201000055A (OSRAM)
NL (2) NL301256I2 (OSRAM)
NO (2) NO2023048I1 (OSRAM)
NZ (1) NZ584229A (OSRAM)
PL (1) PL2207786T3 (OSRAM)
PT (1) PT2207786E (OSRAM)
RS (1) RS52323B (OSRAM)
SA (1) SA08290661B1 (OSRAM)
SI (1) SI2207786T1 (OSRAM)
TW (1) TWI445539B (OSRAM)
UA (1) UA99476C2 (OSRAM)
WO (1) WO2009052287A1 (OSRAM)
ZA (1) ZA201002178B (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522842A (ja) * 2009-04-06 2012-09-27 エーザイ インコーポレイテッド シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用
JP2014177455A (ja) * 2007-10-16 2014-09-25 Eisai Inc シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
SI2695609T1 (sl) 2008-05-15 2020-03-31 Celgene Corporation Oral formulacije anologov citidina in postopki za njihovo uporabo
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100055047A1 (en) * 2008-08-26 2010-03-04 Yiyu Zou Methods for treating bronchial premalignancy and lung cancer
BRPI0923815A2 (pt) * 2008-12-23 2015-07-14 Pharmasset Inc Síntese de nucleosídeos de purina
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
WO2010118010A1 (en) * 2009-04-06 2010-10-14 Eisai Inc. Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer
US8324180B2 (en) 2009-04-06 2012-12-04 Eisai Inc. Compositions and methods for treating cancer
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
SMT201700412T1 (it) 2010-03-31 2017-11-15 Gilead Pharmasset Llc Procedimento per la cristallizzazione di (s)-isopropil 2-(((s)-(perfluorofenossi)(fenossi)fosforil)ammino)propanoato
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
PL2950786T3 (pl) 2013-01-31 2020-05-18 Gilead Pharmasset Llc Formulacja skojarzona dwóch związków przeciwwirusowych
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
CA2926734C (en) * 2013-10-29 2022-03-15 Otsuka Pharmaceutical Co., Ltd. Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
JP7120763B2 (ja) 2014-08-22 2022-08-17 セルジーン コーポレイション 免疫調節化合物を抗体と併用する多発性骨髄腫の治療方法
BR112018011324A2 (pt) * 2015-12-03 2018-12-04 Epidestiny Inc ?composições contendo decitabina, 5azacitidina e tetra-hidrouridina e usos das mesmas?
WO2017158396A1 (en) * 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
CA3091027A1 (en) 2018-02-02 2019-08-08 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
CN113227755B (zh) * 2018-08-28 2025-06-27 上海宜晟生物科技有限公司 测定准确度改善
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
CN112888700B (zh) * 2018-10-19 2025-03-04 因特欧力多公司 具有改善治疗功效的修饰核酸和含有其的抗癌药物组合物
US12448624B2 (en) 2018-10-19 2025-10-21 Interoligo Corporation Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same
EP4041743A4 (en) 2019-10-08 2024-03-13 Otsuka Pharmaceutical Co., Ltd. HIGH PURITY 2'-DEOXY-2',2'-DIFLUORTETRAHYDROURIDINE AND METHOD FOR THE PRODUCTION THEREOF
PT4069254T (pt) 2020-02-25 2024-10-10 Otsuka Pharma Co Ltd Formas sólidas de dosagem oral compreendendo decitabina e cedazuridina
WO2022204126A1 (en) * 2021-03-26 2022-09-29 The Cleveland Clinic Foundation Treatment of rna virus infection with a cytidine deaminase inhibitor
US20240279266A1 (en) * 2021-05-29 2024-08-22 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
US11938143B2 (en) 2021-10-19 2024-03-26 Akirabio, Inc. Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
US20250127806A1 (en) * 2021-11-01 2025-04-24 St. John's University Injectable liquid pharmaceutical composition containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine
TW202410893A (zh) 2022-08-31 2024-03-16 日商大塚製藥股份有限公司 用於治療t細胞淋巴瘤之結合治療

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4275057A (en) * 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE3481172D1 (de) 1983-10-26 1990-03-08 Sheldon B Greer Verfahren und materialien zum empfindlichmachen eines neoplastischen gewebes vor strahlung.
CA1264738A (en) * 1984-12-04 1990-01-23 Eli Lilly And Company Treatment of tumors in mammals
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
EP0543976A4 (en) 1991-04-23 1993-11-10 Oglevee, Ltd. In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) * 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5371210A (en) * 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) * 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en) * 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
CA2118490A1 (en) * 1993-02-23 1994-09-01 Lawrence C. Sowers 4-ethoxy 5-fluoro 2'deoxyuridine
WO1994026761A1 (en) 1993-05-14 1994-11-24 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) * 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
WO1996026743A1 (en) * 1995-03-01 1996-09-06 Human Gene Therapy Research Institute Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) * 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) * 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
ATE339960T1 (de) * 1999-03-01 2006-10-15 Halogenetics Inc Verwendung von zusammensetzungen enthaltend cldc als strahlungssensibilisatoren in der behandlung von neoplastischen erkrankungen
US6933287B1 (en) * 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
AU7018800A (en) 1999-08-26 2001-03-19 Omega Critical Care Limited Improvements relating to catheter positioning
US6462191B1 (en) * 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
CN102241720B (zh) 2000-11-29 2014-01-29 三井化学株式会社 L-核酸衍生物及其合成方法
ATE290882T1 (de) * 2001-01-16 2005-04-15 Glaxo Group Ltd Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
EP2322534A1 (en) 2001-05-18 2011-05-18 Rakesh Kumar Antiviral nucleosides
AU2002322805B2 (en) * 2001-07-31 2007-11-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitor of DNA methylation
US20040002476A1 (en) 2002-02-14 2004-01-01 Stuyver Lieven J. Modified fluorinated nucleoside analogues
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
EP1545558A4 (en) 2002-09-24 2010-02-17 Koronis Pharmaceuticals Inc 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US8158770B2 (en) * 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
WO2006015346A1 (en) 2004-07-30 2006-02-09 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
CN101076535A (zh) 2004-12-08 2007-11-21 西科尔公司 二氟核苷及其制备方法
WO2008085611A2 (en) 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
WO2010118010A1 (en) * 2009-04-06 2010-10-14 Eisai Inc. Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer
WO2010118013A1 (en) * 2009-04-06 2010-10-14 Eisai Inc. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
US8324180B2 (en) * 2009-04-06 2012-12-04 Eisai Inc. Compositions and methods for treating cancer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014177455A (ja) * 2007-10-16 2014-09-25 Eisai Inc シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン
JP2012522842A (ja) * 2009-04-06 2012-09-27 エーザイ インコーポレイテッド シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用

Also Published As

Publication number Publication date
CN101827856B (zh) 2013-02-06
JP2014177455A (ja) 2014-09-25
KR101543049B1 (ko) 2015-08-07
CY2023029I1 (el) 2024-02-16
US20140186335A1 (en) 2014-07-03
SA08290661B1 (ar) 2012-06-10
ATE548374T1 (de) 2012-03-15
FIC20230040I1 (fi) 2023-12-22
BRPI0818672B1 (pt) 2020-10-20
US8951987B2 (en) 2015-02-10
LTC2207786I2 (OSRAM) 2025-09-10
IL204732A0 (en) 2010-11-30
NL301256I2 (nl) 2024-01-11
HK1146410A1 (en) 2011-06-03
GT201000088A (es) 2012-03-13
US9567363B2 (en) 2017-02-14
BRPI0818672A2 (pt) 2015-04-14
RS52323B (sr) 2012-12-31
US8618075B2 (en) 2013-12-31
BRPI0818672B8 (pt) 2021-05-25
PL2207786T3 (pl) 2012-09-28
CN101827856A (zh) 2010-09-08
HUS2300044I1 (hu) 2024-01-28
CR11427A (es) 2010-08-16
EA201000642A1 (ru) 2010-10-29
PT2207786E (pt) 2012-05-28
HRP20120419T1 (hr) 2012-07-31
FR23C1051I2 (fr) 2025-02-07
SI2207786T1 (sl) 2012-10-30
CO6270330A2 (es) 2011-04-20
FR23C1052I1 (fr) 2024-01-26
US20150210730A1 (en) 2015-07-30
TWI445539B (zh) 2014-07-21
ECSP10010095A (es) 2010-07-30
US20090137521A1 (en) 2009-05-28
US8268800B2 (en) 2012-09-18
NI201000055A (es) 2010-08-13
IL204732A (en) 2013-07-31
ES2384011T3 (es) 2012-06-28
AU2008312435A8 (en) 2014-07-24
NO2023048I1 (en) 2023-12-21
EP2207786A1 (en) 2010-07-21
JP2011500713A (ja) 2011-01-06
CY2023028I1 (el) 2024-02-16
NL301257I2 (nl) 2025-11-06
CY1112781T1 (el) 2016-02-10
EP2447272A1 (en) 2012-05-02
ES2616566T3 (es) 2017-06-13
NO2023047I1 (no) 2023-12-21
KR20100091978A (ko) 2010-08-19
TW200924786A (en) 2009-06-16
ME00997B (me) 2012-10-20
HUS2300045I1 (hu) 2024-01-28
NL301256I1 (OSRAM) 2024-01-03
FR23C1052I2 (fr) 2025-02-07
DK2207786T3 (da) 2012-06-18
FIC20230039I1 (fi) 2023-12-22
MX2010004109A (es) 2010-08-10
AU2008312435A1 (en) 2009-04-23
CA2702274A1 (en) 2009-04-23
CA2702274C (en) 2015-12-29
US20120289475A1 (en) 2012-11-15
NZ584229A (en) 2012-06-29
AU2008312435B2 (en) 2014-04-17
EA018757B1 (ru) 2013-10-30
ZA201002178B (en) 2011-05-25
EP2447272B1 (en) 2017-02-01
JP5859588B2 (ja) 2016-02-10
WO2009052287A1 (en) 2009-04-23
LTPA2023539I1 (OSRAM) 2024-02-26
JO2778B1 (en) 2014-03-15
EP2207786B1 (en) 2012-03-07
MY147970A (en) 2013-02-28
LTPA2023538I1 (OSRAM) 2024-02-26
FR23C1051I1 (fr) 2024-01-26
UA99476C2 (en) 2012-08-27

Similar Documents

Publication Publication Date Title
JP5496899B2 (ja) シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン
JP5684787B2 (ja) シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用
TW201102072A (en) Compositions and methods for treating cancer
JP5149168B2 (ja) Ｌｆｍａｕおよびｌｄｔを用いる癌および他の症状または病状の処置方法
JP5687687B2 (ja) 癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体
AU2008312435B8 (en) 2 ' -fluoro-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors
HK1146410B (en) 2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140305

R150 Certificate of patent or registration of utility model

Ref document number: 5496899

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350